Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1

Melissa Cudmore, Shakil Ahmad, Bahjat Al-Ani, Takeshi Fujisawa, Heather Coxall, Kunal Chudasama, Luke R. Devey, Stephen J. Wigmore, Allyah Abbas, Peter W. Hewett, Asif Ahmed

Research output: Contribution to journalArticlepeer-review


Preeclampsia is characterized clinically by hypertension and proteinuria. Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1]) and soluble endoglin (sEng) are elevated in preeclampsia, and their administration to pregnant rats elicits preeclampsia-like symptoms. Heme oxygenase-1 (HO-1) and its metabolite carbon monoxide (CO) exert protective effects against oxidative stimuli. Thus, we hypothesized that HO-1 upregulation may offer protection against preeclampsia by inhibiting sFlt-1 and sEng release.
Original languageEnglish
Pages (from-to)1789-1797
Number of pages9
Issue number13
Early online date26 Mar 2007
Publication statusPublished - 26 Mar 2007


  • endothelium
  • endothelium-derived factors
  • heme oxygenase-1
  • preeclampsia
  • pregnancy
  • statins
  • angiogenesis


Dive into the research topics of 'Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1'. Together they form a unique fingerprint.

Cite this